<DOC>
	<DOCNO>NCT00036621</DOCNO>
	<brief_summary>This clinical trial ass whether BMS-275291 administer safely combination standard adjuvant therapy early breast cancer whether plasma concentration trough exceed target minimum .</brief_summary>
	<brief_title>A Randomized , Placebo-Controlled Trial BMS-275291 Given Daily 12 Months Women With Stage 1c-IIIA Breast Cancer Receiving Adjuvant Chemotherapy and/or Hormonal Therapy</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>1 . Histologically confirm pathologic stage 1cIIIA adenocarcinoma breast completely resect . 2 . Systemic therapy plan accord one follow three regimen : Tamoxifen ( 20mg ) give orally per day Adriamycin ( 60 mg/m2 IV Day 1 ) plus cyclophosphamide ( 600mg/m2 IV Day 1 ) , repeat every 21 day four course ( begin within 8 week definitive surgery ) Adriamycin ( 60mg/m2 IV Day 1 ) plus cyclophosphamide ( 600mg/m2 IV Day 1 ) , repeat every 21 day four course , follow Taxol ( 175mg/m2 IV Day 85 ) repeat every 21 day four course ( begin within 8 week definitive surgery ) . 3 . ECOG performance status 0 1 . 4 . Adequate organ function evidence : ANC &gt; 1500/mm3 Platelets &gt; 100,000/mm3 Serum Creatine &lt; 1.5 ULN Total bilirubin &lt; 1.5 x ULN AST &lt; 2 x ULN 5 . Patients receive adriamycin must LVEF &gt; 50 % acceptable function per institutional practice assess MUGA . 6 . Signed informed consent . 7 . Women age =/ &gt; 18 year 8 . Patients must recover reversible adverse event prior surgery radiation therapy . 9 . Women childbearing potential must serum urine pregnancy test within 72 hour prior start study medication . 1 . Patients breast cancer present margin surgical resection eligible study . Patients suspicious residual disease follow resection eligible . 2 . Prior chemotherapy immunotherapy breast cancer . 3 . Documented metastatic breast cancer . 4 . Other malignancy ( except carcinoma situ cervix surgically treat nonmelanoma skin cancer ) within 5 year study entry . 5 . Pregnant breastfeeding female . 6 . Women child bear potential employ adequate contraception . 7 . History autoimmune disease systemic lupus , rheumatoid arthritis , scleroderma . 8 . Any serious underlying medical condition would impair ability ot patient receive plan treatment may interfere completion trial . 9 . Planned chemotherapy , hormonal therapy biological therapy describe . Patients enrol clinical trial . Use investigational agent permit . 10 . Any condition permit compliance protocol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2007</verification_date>
</DOC>